Leading the way in next-generation propellants (NGPs), protecting tomorrow today

Kindeva is proactively addressing the need for a sustainable future in pulmonary and nasal treatments by offering capabilities in two eco-friendly propellants, HFA152a and HFO1234ze. These propellants boast significantly lower global warming potential (GWP), with HFA152a having 90% lower GWP and HFO1234ze having 99% lower GWP compared to current options.

As one of the first CDMOs to introduce a commercial NGP line for both gases, we have already completed registration batches in 2024 and are set to commence full commercial-scale operations in 2025. We currently operate pilot and two manufacturing lines dedicated to these propellants. This development allows us to provide low-GWP formulations, benefiting the environment and patients alike.

Building on a rich legacy of sustainable innovation, including inventing the pMDI and leading the transition from CFC to HFA propellants, Kindeva possesses deep insight into the challenges of propellant transition. We offer unparalleled expertise in navigating regulatory hurdles, ensuring supply chain reliability, and understanding the physicochemical properties of the new propellants. This comprehensive support, from formulation to commercialization, positions Kindeva as an ideal partner for drug developers seeking to enhance the sustainability of their products.